Research programme: opioid receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: opioid receptor antagonists - GlaxoSmithKline

Alternative Names: GSK 982

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Benzimidazoles; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 21 Aug 2008 Preclinical trials in Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top